Asset profile
reproxalap
Small molecule
Evidence outlook · registrational
Dry Eye Disease: registrational trials complete, results ungraded
Its supporting mid-stage evidence has not yet been graded on this platform. Its registrational studies have completed; results have not been graded on this platform. Check News and the registry record for topline outcomes.
Also in development:Allergic Conjunctivitis · Phase 3
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
2 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 2 same-indication; 1 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Reproxalap: this drug | Phase 3 | Small molecule | — | ||
| Cyclosporine | Approved | — | Calcineurin | ||
| PL9643 | Phase 3 | Peptide | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.